RENB Key Statistics, Chart & Performance
The current stock price of RENB is 1.42 USD. In the past month the price decreased by -37.58%. In the past year, price decreased by -70.98%.
RENB Technical Analysis
RENB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RENB. The financial health of RENB is average, but there are quite some concerns on its profitability.
RENB Financial Highlights
Over the last trailing twelve months RENB reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 59.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.15% | ||
| ROE | -76.11% | ||
| Debt/Equity | 0 |
RENB Forecast & Estimates
RENB Ownership
RENB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.54 | 398.827B | ||
| AMGN | AMGEN INC | 15.03 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.04 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.87 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.12 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.44 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.23 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RENB
Company Profile
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Company Info
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 25
Phone: 14539179840
LUNAI BIOWORKS INC / RENB FAQ
What does RENB do?
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Can you provide the latest stock price for LUNAI BIOWORKS INC?
The current stock price of RENB is 1.42 USD. The price increased by 12.16% in the last trading session.
What is the dividend status of LUNAI BIOWORKS INC?
RENB does not pay a dividend.
How is the ChartMill rating for LUNAI BIOWORKS INC?
RENB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is RENB stock listed?
RENB stock is listed on the Nasdaq exchange.